What is the recommendation for hormone therapy in post-menopausal women after NSTE-ACS?
Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given as new drugs for secondary prevention of coronary events to post-menopausal women after NSTE-ACS and should Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e381 not be continued in previous users unless the benefits outweigh the estimated risks.17,470 472 (Level of Evidence: A)